14 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $8M | -$346M | 0.0% | -4974.3% | -59.5% | -54.6% | -$280M | — | $199M |
| 2024 | $0 | -$234M | — | — | -31.0% | -29.4% | -$184M | — | $143M |
| 2023 | $0 | -$182M | — | — | -19.7% | -18.9% | -$157M | — | $149M |
| 2022 | $9M | -$125M | 0.0% | -1368.9% | -17.4% | -16.6% | -$104M | — | $57M |
| 2021 | $18M | -$79M | 0.0% | -428.4% | -14.3% | -13.8% | -$72M | — | $176M |
| 2020 | $32M | -$29M | 0.0% | -97.3% | -16.8% | -15.2% | -$51M | — | $45M |
| 2019 | $7M | -$42M | 0.0% | -627.0% | -45.2% | -28.2% | -$6M | $16M | $25M |
| 2018 | — | -$34M | — | — | -33.4% | -28.2% | -$35M | $15M | $68M |
| 2017 | — | -$31M | — | — | -85.4% | -66.6% | -$29M | $7M | $20M |
| 2016 | — | -$23M | — | — | -36.0% | -34.1% | — | — | $17M |
| 2015 | — | -$16M | — | — | -25.8% | -24.6% | — | — | $59M |
| 2014 | — | $13M | — | — | 17.9% | 14.9% | — | — | $72M |
| 2013 | — | $12M | — | — | -15.4% | 22.1% | — | — | $38M |
| 2012 | — | -$4M | — | — | 4.8% | — | — | — | $60M |
| Quarter | Revenue | Net income | Gross M | Op M | ROE | ROA | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|---|---|
| Jun '26 | $0 | -$111M | — | — | -8.9% | -8.5% | -$96M | — | $120M |
| Mar '26 | $0 | -$102M | — | — | -7.6% | -7.4% | -$89M | — | $546M |
| Dec '25 | $0 | -$105M | — | — | -18.1% | -16.6% | -$82M | — | $199M |
| Sep '25 | $0 | -$91M | — | — | -16.2% | -15.0% | -$72M | — | $105M |
| Jun '25 | $0 | -$85M | — | — | -13.4% | -12.6% | -$64M | — | $135M |
| Mar '25 | $8M | -$65M | 0.0% | -969.8% | -9.2% | -8.8% | -$62M | — | $117M |
| Dec '24 | $0 | -$66M | — | — | -8.7% | -8.2% | -$55M | — | $143M |
| Sep '24 | $0 | -$63M | — | — | -7.9% | -7.5% | -$50M | — | $88M |
| Jun '24 | $0 | -$58M | — | — | -6.9% | -6.6% | -$33M | — | $137M |
| Mar '24 | $0 | -$48M | — | — | -5.4% | -5.2% | -$46M | — | $59M |
| Dec '23 | — | -$45M | — | — | -4.8% | -4.6% | -$35M | — | $149M |
| Sep '23 | — | -$48M | — | — | -7.6% | -7.2% | -$49M | — | $100M |
| Jun '23 | — | -$47M | — | — | -7.3% | -6.9% | -$35M | — | $65M |
| Mar '23 | — | -$42M | — | — | -6.1% | -5.8% | -$37M | — | $70M |
| Dec '22 | $0 | -$37M | — | — | -5.2% | -5.0% | -$34M | — | $57M |
| Sep '22 | $132000 | -$37M | 0.0% | -28884.8% | -4.9% | -4.8% | -$31M | — | $103M |
| Jun '22 | $536000 | -$31M | 0.0% | -5655.8% | -4.0% | -3.9% | -$17M | — | $370M |
| Mar '22 | $9M | -$20M | 0.0% | -198.1% | -3.6% | -3.5% | -$19M | — | $117M |
| Dec '21 | $4M | -$26M | 0.0% | -664.7% | -4.6% | -4.5% | -$21M | — | $176M |
| Sep '21 | $8M | -$15M | 0.0% | -192.0% | -6.2% | -5.8% | -$15M | — | $88M |
How the market has priced XENE against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Xenon Pharmaceuticals Inc.'s revenue has declined 25.3% per year. These are computed facts, not advice.
As of FY2025, Xenon Pharmaceuticals Inc. reported — of total debt against $199M of cash.
In FY2025, gross margin was —, operating margin -4974.3%, and net margin -4612.1%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.